Search for Terms or Answers
Search for Terms or Answers
Results for “JAK inhibitors”
Science Daily · Mar 25, 2025
Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since their approval, the indications for these medical drugs have steadily increased, but recently safety…
Jack Cush, MD · Feb 18, 2026
In 2020, the ACR Recommendations on Reproductive Health notably avoided firm guidance on the use of JAK inhibitors (JAKi) during pregnancy stating, "There is no available evidence regarding use or safety of the new small- molecule agents, tofacitinib, baricitinib, and apremilast, during pregnancy."
Janet Pope, MD, MPH, FRCPC · Jun 24, 2024
There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.
Jun 14, 2025
Dr. David Liew reports on abstract POS0150 - Evolution of Janus Kinase Inhibitors (JAKi) Prescriptions Since 2015 In An International Collaboration of Rheumatoid Arthritis Registers (The 'JAK-pot' Study): Effect of Regulatory Warnings - presented at the 2025 EULAR meeting in Barcelona, Spain.
Medpage Today · Jun 5, 2024
A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs had failed, a pragmatic head-to-head trial found.Patients randomized to baricitinib (Olumiant) for 12…
Jack Cush, MD · Sep 16, 2025
JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for the treatment of immune-mediated inflammatory diseases (IMIDs).Safety…
Janet Pope, MD, MPH, FRCPC · Nov 29, 2024
When should you consider off-label use of JAKi?
David Liew, FRACP · Nov 17, 2024
The SELECT-GCA study, looking at upadacitinib in GCA, anchored the ACR 2024 opening plenary for a reason - it is highly notable and badly needed.
Jun 13, 2024
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Jack Cush, MD · Jun 27, 2024
Trials are underway evaluating the potential benefits of JAK inhibitors (JAKi) in giant cell arteritis (GCA) patients who are refractory to standards of care. An observational real-world analysis of a small worldwide cohort suggests the utility of JAKi in GCA. This retrospective analysis…
ALau · Oct 31, 2018
ACR 2018 has come and gone. It was a conference filled with a number of highlights. One thing from this conference which really stood out was the continued plethora of data on JAK inhibitors. First in RA, and now in psoriatic arthritis and psoriasis.There was a time when the gold standard of a new…
Mepage Today · Jul 18, 2024
Insurance claims data showed that patients with autoimmune disorders who took Janus kinase (JAK) inhibitors had lower rates of age-related macular degeneration (AMD), hinting that the drugs might treat the common eye disease.Compared to patients on other immune-modulating drugs, those taking JAK…
Mrinalini Dey, MD · Jun 4, 2026
At EULAR 2026, two large phase 3 studies highlight that the JAK story in axSpA is still evolving rapidly, with different selectivity profiles and expanding global development programs continuing to push the field forward.
MedPage Today · Jan 21, 2026
Among rheumatoid arthritis (RA) patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of phase III trial data.
jjcush · Feb 19, 2020
Science Translational Medicine has a report on how the use of Janus kinase (JAK) inhibitors may boost osteoblasts to battle bone erosions in conditions like rheumatoid arthritis (RA).JAK inhibitors have been shown in clinical trials to retard the development of bone erosions while controlling…
Sep 7, 2021
Dr. Jack Cush is joined by rheumatology colleagues to discuss impressions and impact of the 9/1/21 FDA Drug Safety Communication to physicians regarding new label changes, adding new (Boxed) Warnings for cardiovascular and cancer risks with the use of JAK inhibitors (tofacitinib, baricitinib, upadacitinib) in inflammatory arthritis patients. The Video discussion includes Drs. Kathryn Dao (Dallas), Rachel Tate (Palm Beach), William Shergy (Huntsville), Jeffrey Sparks (Boston), and Jack Cush (Dallas). Author Disclosures Jack Cush, MD: Advisor/Consultant: Abbvie, Novartis, Amgen, BMS. (Investigator on Pfizer 1133 trial) Rachel Tate, MD: Speakers bureau for Abbvie Kathryn Dao, MD: Nothing to disclose Jeffrey Sparks, MD: research support from Bristol-Myers Squibb and consultancy for AbbVie, Bristol-Myers Squibb, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer. William Shergy, MD: Speaker for Amgen, Pfizer, and AbbVie; Clinical trials with AbbVie, Amgen, BMS, Gilead, and Pfizer,
MedPage Today · Sep 25, 2024
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.Three months after starting a new targeted RA therapy, patients on Janus kinase (JAK) inhibitors reported…
Md Yuzaiful Md Yusof, MRCP(UK), PhD · Jun 14, 2024
The development of JAK inhibitors represents an advance for the treatment of inflammatory rheumatic diseases. However, the enthusiasm in using this target has waned since the publication of the ORAL surveillance clinical trial in 2022. Subsequently, both the FDA and EMA issued a warning on using JAKi in patients with certain risk factors, e.g., ≥65 years, at increased risk of MACE, current smoker or past smoker and at increased risk of cancer, should other alternative treatment be available. So, how has this warning impacted on JAKi development and use?
Jun 13, 2024
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
Sponsored by AbbVie Medical Affairs + Health Impact
Click to download or view mobile versionUPADACITINIB INDICATIONS, IMPORTANT SAFETY CONSIDERATIONS AND BOXED WARNINGINDICATIONS Upadacitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of: Adults with moderately to severely active rheumatoid arthritis (RA) who have…
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
